Form 4: CCRN Director Receives Restricted Stock Grant Post-Merger Termination

Cross Country Healthcare Director Venkat Bhamidipati was granted 18,680 restricted shares of common stock, vesting on December 18, 2025, following a terminated merger agreement.

Summary

• Venkat Bhamidipati, a Director of Cross Country Healthcare, Inc. (CCRN), acquired 18,680 shares of common stock.
• The transaction occurred on December 18, 2025, with a reported price of $0 per share, indicating a restricted stock grant.
• Following this transaction, Venkat Bhamidipati beneficially owns 29,759 shares of common stock.
• These restricted shares (RSAs) are scheduled to vest on December 18, 2025.
• The Compensation Committee of the Company's Board of Directors approved the grant date of December 18, 2025, for these RSAs, a change from the previously planned March 31, 2025.
• This adjustment to the grant date followed the termination of a Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the director's increased equity alignment, which is generally favorable for shareholders. However, the underlying context of a terminated merger agreement introduces a degree of uncertainty, preventing a higher score.

Positives

• The grant of restricted shares to a director further aligns management's interests with those of shareholders, promoting long-term value creation.

Negatives

• The termination of the Merger Agreement with Aya Holdings II Inc., Spark Merger Sub One Inc., and Aya Healthcare, Inc. on December 3, 2025, represents a missed strategic opportunity or a change in corporate direction.

Risks

• The termination of a significant merger agreement could introduce strategic uncertainty regarding the company's future growth plans and market position.
• Changes in compensation schedules, even if explained, can sometimes signal underlying operational or strategic shifts that warrant further scrutiny.

Future Outlook

The restricted shares granted are scheduled to vest on December 18, 2025, indicating a future alignment of the director's interests with the company's performance up to that date. The company's strategic direction following the terminated merger agreement remains a key area for future observation.

Industry Context

This filing reflects an internal compensation adjustment for a director at Cross Country Healthcare, a company operating in the healthcare staffing and workforce solutions industry. The termination of a merger agreement, as noted in the filing, could signal a shift in the company's strategic growth initiatives within a competitive and evolving healthcare sector.

Corporate Governance

Related Party Transactions

• The grant of restricted shares to a director constitutes a form of related party compensation, aligning the director's financial interests with the company's performance.

Stakeholder Impact

• Shareholders: The increased equity ownership by a director enhances alignment between management and shareholder interests.
• Employees/Management: The director's compensation structure is adjusted, potentially influencing morale and retention at the leadership level.

Next Steps

• The 18,680 restricted shares of common stock granted to Director Venkat Bhamidipati are scheduled to vest on December 18, 2025.

Key Dates

Keywords

CROSS COUNTRY HEALTHCARE, CCRN, Form 4, Insider Transaction, Restricted Stock Award, Director Compensation, Equity Grant, Merger Termination, Corporate Governance